Law360, New York (October 14, 2011, 9:44 PM ET) -- GlaxoSmithKline PLC on Friday agreed to pay $49 million to end class action claims from direct purchasers of Wellbutrin SR accusing the drugmaker of filing baseless patent suits to delay generic competition in the market for the antidepressant.
In a motion filed in the Eastern District of Pennsylvania, the direct purchaser class asked the court for final approval of the settlement, which includes a $49 million in cash plus up to $500,000 to cover the costs of notifying the class and administering the settlement.
"The proposed...
GSK Settles Direct Buyers' Wellbutrin Claims For $49M
To view the full article, take a free trial now.
